Ken Griffin Senseonics Holdings, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$0.32 - $0.49 $5,344 - $8,183	16,700 Added 8.97%	202,800 $70,000
Q2 2024 Aug 14, 2024	BUY	$0.37 - $0.52 $518 - $728	1,400 Added 0.76%	186,100 $74,000
Q1 2024 May 15, 2024	SELL	$0.5 - $0.73 $106,500 - $155,490	-213,000 Reduced 53.56%	184,700 $97,000
Q4 2023 Feb 14, 2024	BUY	$0.48 - $0.7 $8,064 - $11,760	16,800 Added 4.41%	397,700 $226,000
Q3 2023 Nov 14, 2023	SELL	$0.5 - $1.05 $8,800 - $18,480	-17,600 Reduced 4.42%	380,900 $228,000
Q2 2023 Aug 14, 2023	SELL	$0.55 - $0.89 $16,335 - $26,433	-29,700 Reduced 6.94%	398,500 $302,000
Q1 2023 May 15, 2023	SELL	$0.68 - $1.25 $228,888 - $420,750	-336,600 Reduced 44.01%	428,200 $304,000
Q4 2022 Feb 14, 2023	BUY	$0.96 - $1.34 $135,552 - $189,208	141,200 Added 22.64%	764,800 $787,000
Q3 2022 Nov 14, 2022	SELL	$1.02 - $2.23 $121,278 - $265,147	-118,900 Reduced 16.01%	623,600 $823,000

142

59.9M

393K

254K

Ticker SENS
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 465,447,008
Market Cap $149M
Description
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.